Last reviewed · How we verify
Lamotrigine monotherapy
At a glance
| Generic name | Lamotrigine monotherapy |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- PET and MRI Brain Imaging of Bipolar Disorder (NA)
- Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy (NA)
- Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy (PHASE3)
- A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures (PHASE4)
- A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil (PHASE1)
- Premenstrual Dysphoric Disorder and Antiepileptic Drugs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamotrigine monotherapy CI brief — competitive landscape report
- Lamotrigine monotherapy updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI